RxDoctor Payments Data

Eric Carlson, MD

Medical Oncology · Joplin, MONPI 1417926015

Payments from drug & device makers

$14,244in general payments, 2019–2025

Across 626 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$943
  • Rigel Pharmaceuticals, Inc.$905
  • Novartis$869
  • AstraZeneca$854
  • Karyopharm Therapeutics Inc.$840
  • E.r. Squibb & Sons, L.L.C.$833
  • plus $9K from 54 others

What the payments were for

  • Consulting fees$1,2509%
  • Speaking & faculty fees$9577%
  • Food & beverage$11,77983%
  • Education$2582%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer92$943
Rigel Pharmaceuticals, Inc.5$905
Novartis51$869
AstraZeneca(2 entities)35$854
Karyopharm Therapeutics Inc.6$840
E.r. Squibb & Sons, L.L.C.37$833
Daiichi Sankyo Inc.21$593
Sanofi29$505
Verity Pharmaceuticals Inc.1$500
Johnson & Johnson19$498
Gilead(2 entities)20$419
Genentech USA, Inc.23$372
Amgen26$353
AbbVie(2 entities)14$341
Regeneron Healthcare Solutions, Inc.11$322
Bristol Myers Squibb16$262
Array Biopharma Inc15$262
Merck15$255
GSK10$254
Astellas Pharma US Inc14$252
EMD Serono, Inc.14$236
Lilly USA, LLC10$231
Genentech, Inc.2$215
Incyte Corporation12$214
Exelixis Inc.8$191
Takeda Pharmaceuticals U.S.A., Inc.7$173
Eisai Inc.11$166
Galvanize Therapeutics, Inc1$156
Bayer8$151
Seagen Inc.9$143
AVEO Pharmaceuticals, Inc.3$130
Beone Medicines USA, Inc.1$125
Janssen Scientific Affairs, LLC3$116
Foundation Medicine, Inc.1$107
Sobi, Inc5$106
Epizyme, Inc.3$102
Boehringer Ingelheim4$102
Beigene USA, Inc.6$86
Genmab U.S., Inc.3$82
Taiho Oncology, Inc.4$71
Puma Biotechnology, Inc.4$67
Acrotech Biopharma Inc.5$65
Mylan Institutional Inc.3$62
Blueprint Medicines Corporation3$54
Pharmacyclics LLC, An Abbvie Company3$49
Blue Earth Diagnostics3$48
Pharmacosmos Therapeutics Inc.2$47
Kyowa Kirin, Inc.3$46
G1 Therapeutics, Inc.2$35
Jazz Pharmaceuticals Inc.1$34
Agios Pharmaceuticals, Inc.2$34
Aurobindo Pharma USA, Inc.2$30
Springworks Therapeutics, Inc.1$29
Pharmaessentia USA Corporation1$26
Coherus Oncology, Inc.1$22
Sumitomo Pharma America, Inc.1$22
Tolmar, Inc.1$21
Bioventus LLC1$21
ADMA Biomanufacturing LLC1$21
Servier Pharmaceuticals LLC1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,244 in reported general payments places this provider in the 35th percentile of 144 medical oncology providers in Missouri.

See all medical oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$56,437
Medicare patients
157
Services billed
569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate27$393,732
PomalystPomalidomide14$327,382
XareltoRivaroxaban19$11,051
EliquisApixaban12$6,951
Anastrozole72$558
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen23$427
Ondansetron Hcl17$369
Hydromorphone Hcl16$357
Dexamethasone20$291
Lidocaine-PrilocaineLidocaine/Prilocaine20$248
Oxycodone Hcl12$206
Letrozole19$205
Prochlorperazine Maleate17$132
Hydroxyurea12$127
Prednisone15$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$854$393,73227 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$833$327,38214 claims
Johnson & JohnsonXarelto$498$11,05119 claims
PfizerEliquis$943$6,95112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 144 medical oncology providers in Missouri.

Other medical oncology in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →